Zeo ScientifiX Files 8-K with Corporate Updates
Ticker: ZEOX · Form: 8-K · Filed: Dec 19, 2024 · CIK: 1557376
Sentiment: neutral
Topics: corporate-action, filing-update
TL;DR
Zeo ScientifiX filed an 8-K on Dec 17, 2024, reporting corporate amendments and financial exhibits.
AI Summary
Zeo ScientifiX, Inc. filed an 8-K on December 19, 2024, reporting events as of December 17, 2024. The filing indicates amendments to its articles of incorporation or bylaws and includes financial statements and exhibits. The company, formerly known as Organicell Regenerative Medicine, Inc., is incorporated in Nevada and operates in the biological products sector.
Why It Matters
This 8-K filing signals potential changes in Zeo ScientifiX's corporate structure or governance, which could impact its operational direction and investor relations.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not appear to contain immediate negative financial or operational news.
Key Players & Entities
- Zeo ScientifiX, Inc. (company) — Registrant
- Organicell Regenerative Medicine, Inc. (company) — Former company name
- December 17, 2024 (date) — Date of earliest event reported
- December 19, 2024 (date) — Filing date
- Nevada (jurisdiction) — State of incorporation
FAQ
What specific amendments were made to Zeo ScientifiX's articles of incorporation or bylaws?
The filing indicates that amendments were made, but the specific details of these amendments are not provided in the summary text.
What is the nature of the financial statements and exhibits included in this filing?
The filing states that financial statements and exhibits are included, but their specific content is not detailed in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on December 17, 2024.
What was Zeo ScientifiX, Inc. formerly known as?
Zeo ScientifiX, Inc. was formerly known as Organicell Regenerative Medicine, Inc.
In which state is Zeo ScientifiX, Inc. incorporated?
Zeo ScientifiX, Inc. is incorporated in Nevada.
Filing Stats: 644 words · 3 min read · ~2 pages · Grade level 11.5 · Accepted 2024-12-19 16:05:26
Filing Documents
- zeoscientifix_8k.htm (8-K) — 27KB
- zeoscientifix_ex3-1.htm (EX-3.1) — 9KB
- ex3-1_001.jpg (GRAPHIC) — 1014KB
- ex3-1_002.jpg (GRAPHIC) — 501KB
- 0001829126-24-008411.txt ( ) — 2243KB
- ocel-20241217.xsd (EX-101.SCH) — 3KB
- ocel-20241217_lab.xml (EX-101.LAB) — 33KB
- ocel-20241217_pre.xml (EX-101.PRE) — 22KB
- zeoscientifix_8k_htm.xml (XML) — 3KB
03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On December 17, 2024, we filed an Amendment (the " Amendment ") to the Certificate of Designation (the " Certificate of Designation ") of our Series C Non-Convertible Preferred Stock (the " Series C Preferred Shares ") with the Secretary of State of Nevada. The Series C Preferred Shares were acquired by Skycrest Holdings, Inc. (" Skycrest ") and Greyt Ventures LLC (" Greyt ") in a " change in control " transaction" consummated in August 2022. The Series C Preferred Shares vote together with shares of our common stock as a single class on all matters presented to a vote of stockholders, except as required by law and entitle Skycrest and Greyt to each exercise 25.5% of the total voting power of the Company. The Amendment amends the redemption provision of the Certificate of Designation to (i) provide that the Series C Preferred Shares may be assigned with the prior consent of our board of directors without triggering the redemption provision; and (ii) change the threshold of ownership of the common stock acquired by Skycrest or Greyt contemporaneously with the acquisition by them of the Series C Preferred Shares below which the redemption provision would be triggered. Reference is made to the copy of the Amendment filed as Exhibit 3.1 to this Report.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 3.1 Amendment to Certificate of Designation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 19, 2024 ZEO SCIENTIFIX, INC. By: /s/ Ian T. Bothwell Ian T. Bothwell Interim Chief Executive Officer and Chief Financial Officer 2